Crivellari D,Pagani O,Veronesi A,et al. Intemational breast can cer study g roup. High incidence of central nervous system involvement in patients with met a static or locally advanced breast cancer treated with epirubicin and docetaxel[ J]. Ann Oncol,2001,12:353-356.
[2]
Abali H,Celik I. High incidence of central nervous system involvement i n pat ients with breast cancer treated with epirubicin and docetaxel[J]. Am J Clin Oncol,2002,25:632 -633.
[3]
Chang J,Clark GM,Allred DC,et al. Survival of patients with metastat ic b reast carcinoma:importance of prognostic markers of theprimary tumor[J]. Canc er,2003,97:545-553.
[4]
Engel J,Eckel R,Aydemir U,et al. Determinants and prognoses of locore giona l and distant progression in breast cancer[J]. Int J Radiat Oncol Biol Phys ,2003,55:1186 -1195
[5]
Samanan NA,Buzdar AU,Aldinger KA,et al. Estrogen receptor:a prognost ic factor in breast cancer[J]. Cancer,1981,47:554-560.
[6]
Stewart JF,King RJ,Sexton SA,et al. Oestrogen receptors,sites of met astat ic disease and survival in recurrent breast cancer[J]. Eur J Cancer,1981,1 7:449 -453.
[7]
Bendell JC,Domchek SM,Burstein HJ,et al. Centra nervous system metast ases in women who receive trastuzumab-based therapy for metastatic breast carcinoma[ J]. Cancer,2003,97:2972-2977.
[8]
Miller KD,Weathers T,Haney LG,et al. Occult central nervous system in volvem ent in patients with metastatic breast cancer:prevalence,predictive factors and impact on overall survival[J]. Ann Oncol,2003,14:1072-1077.
